Clinical course of thoracic cancers in Hodgkin's disease survivors

Annals of Oncology

Volumn 16, Issue 5, 2005, Pages 793-797

  Das, Praj ^a   Ng, A K ^b   Stevenson, M A ^c   Mauch, P M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Hodgkin's disease; Lung cancer; Risk factors; Second malignancy; Survival; Thoracic neoplasm

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; MALE; MEDICAL RECORD; MULTIMODALITY CANCER THERAPY; PHYSICAL EXAMINATION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY; SMOKING HABIT; SURVIVAL TIME; THORAX RADIOGRAPHY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE OF ONSET; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; COMORBIDITY; FEMALE; HODGKIN DISEASE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MASSACHUSETTS; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; RESPIRATORY TRACT NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 20044391983     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi155     Document Type: Article

References (31)

1. Straus DJ, Yahalom J, Gaynor J et al. Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate-stage Hodgkin's disease. Cancer 1992; 69: 1052-1060.
2. Horning S, Hoppe R, Mason J et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 1997; 15: 1736-1744.
3. Carde P, Noordijk E, Hagenbeek A et al. Superiority of EBVP chemotherapy in combination with involved field radiation therapy over subtotal nodal irradiation in favorable clinical stage I-II Hodgkin's disease: The EORTC-GPMC H7F randomized trial. Proc Am Soc Clin Oncol 1997; 16: (Abstr 13).
4. Sieber M, Engert A, Diehl V. Treatment of Hodgkin's disease: Results and current concepts of the German Hodgkin's Lymphoma Study Group. Ann Oncol 2000; 11: 81-85.
5. Henry-Amar M, Somers R. Survival outcome after Hodgkin's disease: A report from the International Data Base on Hodgkin's disease. Semin Oncol 1990; 17: 758-768.
6. Mauch PM, Kalish LA, Marcus KC et al. Long-term survival in Hodgkin's disease. Cancer J Sci Am 1995; 1: 33.
7. Hudson MM, Poquette CA, Lee J et al. Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol 1998; 16: 3592-3600.
8. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996; 6: 225-242.
9. Donaldson SS, Hancock SL, Hoppe RT. The Janeway lecture: Hodgkin's disease - Finding the balance between cure and late effects. Cancer J Sci Am 1999; 5: 325-333.
10. Ng AK, Bernardo MP, Weller E et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20: 2101-2108.
11. van Leeuwen FE, Somers R, Taal BG et al. Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol 1989; 7: 1046-1058.
12. van Leeuwen FE, Klokman WJ, Veer MB et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487-497.
13. Swerdlow AJ, Barber JA, Hudson GV et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000; 18: 498-509.
14. Ng AK, Bernardo MVP, Weller E et al. Second malignancy after Hodgkin's disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002; 100: 1989-1996.
15. Dores GM, Metayer C, Curtis RE et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 2002; 20: 3484-3494.
16. Abrahamsen AF, Andersen A, Nome O et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-time. Ann Oncol 2002; 13: 1786-1791.
17. List AF, Doll DC, Greco FA. Lung cancer in Hodgkin's disease: Association with previous radiotherapy. J Clin Oncol 1985; 3: 215-221.
18. Kaldor JM, Day NE, Bell J et al. Lung cancer following Hodgkin's disease: a case-control study. Int J Cancer 1992; 52: 677-681.
19. van Leeuwen FE, Klokman WJ, Stovall M et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995; 87: 1530-1537.
20. Swerdlow AJ, Schoemaker MJ, Allerton R et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001; 19: 1610-1618.
21. Travis LB, Gospodarowicz M, Curtis RE et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94: 182-192.
22. Lerman Y, Learman Y, Schachter P et al. Radiation associated malignant pleural mesothelioma. Thorax 1991; 46: 463-464.
23. Weissmann LB, Corson JM, Neugut AI, Antman KH. Malignant mesothelioma following treatment for Hodgkin's disease. J Clin Oncol 1996; 14: 2098-2100.
24. Henschke CI, McCauley DI, Yankelevitz DF et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354: 99-105.
25. Henschke CI, Naidich DP, Yankelevitz DF et al. Early Lung Cancer Action Project: initial findings on repeat screening. Cancer 2001; 92: 153-159.
26. Swensen SJ, Jett JR, Sloan JA et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 2002; 165: 508-513.
27. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
28. Laurie SA, Kris MG, Portlock CS et al. The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin's disease. Cancer 2002; 95: 119-126.
29. Fontana RS, Sanderson DR, Woolner LB et al. Lung cancer screening: the Mayo program. J Occup Med 1986; 28: 746-750.
30. Kubik A, Parkin DM, Khlat M et al. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 1990; 45: 26-33.
31. Das P, Ng AK, Earle CC et al. Cost-effectiveness of computed tomography screening for lung cancer in Hodgkin's disease survivors. Int J Rad Oncol Biol Phys 2003; 57 (Suppl): S213 (Abstr).